AI blood test pioneer Cardio Diagnostics targets heart disease

Cardiovascular disease remains one of the most serious and costly health challenges worldwide, driving an urgent need for earlier detection and more precise, personalized treatment strategies. Cardio Diagnostics Holdings (NASDAQ: CDIO) is focused on addressing this need by developing advanced solutions that leverage artificial intelligence (“AI”) and multi-omic biomarkers to deliver actionable insights from a simple blood sample, enabling more informed and timely cardiac care decisions. The scale and impact of cardiovascular disease underscore why innovation in this area is so critical. According to the Centers for Disease Control and Prevention, heart disease remains the leading cause of death in the United States, responsible for approximately one in every three deaths. Beyond mortality, the economic burden is staggering, with direct and indirect costs projected to exceed $1 trillion annually by 2035.

Advances in genomics and epigenetics are making it possible to better understand how genetic predisposition and environmental influences interact to drive disease progression. By utilizing a simple blood test, Cardio Diagnostics is lowering barriers to advanced cardiovascular testing. The company's AI-driven platform integrates genetic, epigenetic, and clinical data to provide a comprehensive risk assessment, potentially allowing for earlier intervention and more personalized treatment plans. This approach could shift the paradigm from reactive treatment to proactive prevention, ultimately improving patient outcomes and reducing healthcare costs.

The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO. For more information, read the full release at Read More.